ACE-083: adverse events and evidence limits
Local intramuscular ACE-083 in adults with facioscapulohumeral muscular dystrophy produced local reactions, myalgia and swelling. Investigators considered a peroneal nerve injury with improving but persistent weakness probably treatment-related. [1]
Related events prompted some withdrawals. Without complete tables, frequencies were not calculated; these findings do not establish systemic-use safety. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Local reactions at the injection site | Adults with facioscapulohumeral muscular dystrophy, local intramuscular administration | Described without a frequency; the publication gives no complete frequency tables | [1] |
| Myalgia | The same participants | Described without a frequency | [1] |
| Swelling | The same participants | Described without a frequency | [1] |
| Peroneal nerve injury with persistent weakness | The same participants | Investigators considered it probably treatment-related; no frequency given | [1] |
| Withdrawals due to related events | The same participants | Some related events prompted withdrawals; frequencies were not calculated | [1] |
References
- Jeffrey M Statland et al. (2022). Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy https://doi.org/10.1002/mus.27558.